214450 — PharmaResearch Co Balance Sheet
0.000.00%
- KR₩5tn
- KR₩4tn
- KR₩350bn
- 92
- 11
- 64
- 60
Annual balance sheet for PharmaResearch Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 79,267 | 156,798 | 184,343 | 160,298 | 437,351 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 26,351 | 30,510 | 36,415 | 36,330 | 56,624 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 127,404 | 206,792 | 247,345 | 256,465 | 554,542 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 94,046 | 109,481 | 117,960 | 123,061 | 147,313 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 319,831 | 427,647 | 478,055 | 535,281 | 855,701 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 35,849 | 48,005 | 54,253 | 65,899 | 82,818 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 74,409 | 122,205 | 134,552 | 102,178 | 316,299 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 245,423 | 305,442 | 343,503 | 433,104 | 539,402 |
| Total Liabilities & Shareholders' Equity | 319,831 | 427,647 | 478,055 | 535,281 | 855,701 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |